Dr. Omar Alshaer presents a real patient case*:

A case study of HR+, HER2- ABC with metastases beyond the bone, a concerning clinical characteristic1-4

Disease characteristics that typically confer a less favorable prognosis. Visceral and bone metastases were a concerning clinical characteristic in MONARCH 2. Pre-planned subgroup analyses of OS and PFS were performed in the pre- or perimenopausal population.

For more information, see page 5.

 

Dr. Omar Alshaer, MD, is Head Section of medical oncology on Security Forces Hospital in Riyadh.


*Patient name is kept anonymous to maintain confidentiality

 

This case study presents a real patient and disease characteristics. The efficacy of abemaciclib in combination with fulvestrant (FUL) is sourced from MONARCH 2, the Verzenio + FUL trial.

 

This clinical case presentation has been sponsored by Eli Lilly and Company.

 

Verzenio is indicated for the treatment of hormone receptor–positive (HR+), human epidermal growth factor receptor 2–negative (HER2−) advanced or metastatic breast cancer (MBC)1:

  In combination with fulvestrant for women with disease progression following endocrine therapy

  In combination with an aromatase inhibitor (AI) for postmenopausal women as initial endocrine-based therapy

  As a single agent for adult patients with disease progression following endocrine therapy and prior chemotherapy in the metastatic setting

 

 

PP-AL-SA-0390

Please see Select Important Safety Information throughout, and full Prescribing Information for Verzenio.

Categories: All articles

0 Comments

Leave a Reply

Your email address will not be published. Required fields are marked *